J&J, tiny RNA biotech Arcturus combine for hepatitis B work by Ben Adams Thursday, October 19, 2017 Johnson & Johnson has notched a deal with Arcturus Therapeutics to help with its new focus on hepatitis B.
NuCana plans $115M IPO to test retooled chemotherapies by Nick Paul Taylor Wednesday, September 6, 2017 The anticipated haul will fund late-phase trials of NuCana’s reformulated cancer candidates, including a version of Eli Lilly’s Gemzar.
Medivir sells Chinese rights to hepatitis C drug to Ascletis by Nick Paul Taylor Friday, August 18, 2017 The deal continues the retreat from infectious diseases Medivir began after Gilead and others cornered the hepatitis C market.
Newsummit Biopharma licenses hepatitis C antibody from charity group by Angus Liu Wednesday, March 15, 2017 Chinese CRO Newsummit Biopharma has received a license to a hepatitis C antibody from MRC Technology, a medical research charity.
AbbVie looks to battle Gilead with new hep C data by Ben Adams Monday, April 18, 2016 Although a little late to the game, AbbVie is touting impressive cure rates for its new daily hep C combo as it looks to find a bigger wedge in a market dominated by Gilead.